- $382.57m
- $334.48m
- $10.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 38.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -162.91% | ||
| Return on Equity | -526.34% | ||
| Operating Margin | -1149.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 88.52 | 2.05 | 2.6 | n/a | 10 | 10.75 | 74.43 | -10.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Directors
- Daniel Paterson PRE (59)
- Brian Stuglik CEO (62)
- Robert Gagnon CFO (46)
- Michael Kauffman LED (57)
- Paul Bunn DRC
- Michelle Robertson DRC (54)
- Lesley Solomon DRC
- Timothy Barberich IND (73)
- John Johnson IND (63)
- Eric Rowinsky IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 4th, 2010
- Public Since
- November 8th, 2011
- No. of Shareholders
- 7
- No. of Employees
- 78
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 51,489,998
- Address
- 117 Kendrick Street, Suite 500, NEEDHAM, 02494
- Web
- https://www.verastem.com/
- Phone
- +1 7812924200
- Contact
- Julissa Viana
- Auditors
- Ernst & Young LLP
Latest News for VSTM
Upcoming Events for VSTM
Q1 2025 Verastem Inc Earnings Release
Verastem Inc at HC Wainwright BioConnect Investor Conference
Verastem Inc at RBC Capital Markets Global Healthcare Conference
Verastem Inc at Alliance Global Partners Healthcare Company Showcase (Virtual)
Verastem Inc Annual Shareholders Meeting
Verastem Inc Annual Shareholders Meeting
Q2 2025 Verastem Inc Earnings Release
Similar to VSTM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 05:57 UTC, shares in Verastem are trading at $7.43. This share price information is delayed by 15 minutes.
Shares in Verastem last closed at $7.43 and the price had moved by -28.28% over the past 365 days. In terms of relative price strength the Verastem share price has underperformed the S&P500 Index by -35.33% over the past year.
The overall consensus recommendation for Verastem is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVerastem does not currently pay a dividend.
Verastem does not currently pay a dividend.
Verastem does not currently pay a dividend.
To buy shares in Verastem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.43, shares in Verastem had a market capitalisation of $382.57m.
Here are the trading details for Verastem:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VSTM
Based on an overall assessment of its quality, value and momentum Verastem is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Verastem is $13.38. That is 80.08% above the last closing price of $7.43.
Analysts covering Verastem currently have a consensus Earnings Per Share (EPS) forecast of -$2.54 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verastem. Over the past six months, its share price has outperformed the S&P500 Index by +90.41%.
As of the last closing price of $7.43, shares in Verastem were trading +65.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Verastem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Verastem's management team is headed by:
- Daniel Paterson - PRE
- Brian Stuglik - CEO
- Robert Gagnon - CFO
- Michael Kauffman - LED
- Paul Bunn - DRC
- Michelle Robertson - DRC
- Lesley Solomon - DRC
- Timothy Barberich - IND
- John Johnson - IND
- Eric Rowinsky - IND